Skip to content
Screener

Cumberland Pharmaceuticals CPIX Q1 2026 earnings

Reported May 5, 2026 · Before market open

Revenue$9.1MBeat by $628.3K
EPS-$0.13In line
Revenue estimate$8.5M
EPS estimate-$0.13

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$8.5M
EPS estimate-$0.13

Financials

Q1 2026

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$48.61M-17.7%
Enterprise value$42.43M-13.7%
P/S1.5×+0.1×

Profitability

See full
Gross margin77.2%-7.1pp
Operating margin-30.4%-47.1pp
Net margin-23.5%-48.4pp
FCF margin4.4%—

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio1×-0.3×

Segments

By product

See full
Sancuso$2.9M+29.8%
Vibativ$2.1M-29.4%
Talicia$1.9M—
Other revenue$168.9K-94.6%

FAQ

When did Cumberland Pharmaceuticals report Q1 2026 earnings?
Cumberland Pharmaceuticals (CPIX) reported Q1 2026 earnings on May 5, 2026 before market open.
What were Cumberland Pharmaceuticals's Q1 2026 revenue and EPS?
Cumberland Pharmaceuticals reported revenue of $9.1M and eps of $-0.13 for Q1 2026.
Did Cumberland Pharmaceuticals beat estimates in Q1 2026?
Revenue beat the consensus estimate of $8.5M by $628.3K. EPS beat the consensus estimate of $-0.13 by $0.00.
How did Cumberland Pharmaceuticals's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 22.0% from $11.7M a year earlier.
Where can I find Cumberland Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001087294-26-000046) and the 10-Q periodic report (0001087294-26-000049) directly on SEC EDGAR. The filing index links above go to sec.gov.